RFK Jr.’s Blue Elixir: Methylene Blue, Its Benefits and Risks

A recent video showing Robert F. Kennedy Jr. adding a blue liquid to his water on a flight has ignited a flurry of online speculation and discussion surrounding Methylene Blue (MB). Social media users are buzzing about its purported benefits, ranging from radiation protection to cold prevention, while experts and health professionals are urging caution, particularly regarding dosage and potential side effects.

The Viral Video and Online Reactions

The video, which quickly went viral, shows RFK Jr., 71, adding a blue liquid from a dropper into his water. This prompted speculation that it was Methylene Blue.

The online response has been varied, with some users touting MB as a “strong cancer cure and powerful prevention,” while others questioned the potential health implications, particularly given Kennedy Jr.’s age and past health issues. MMA fighter Vance Elrod weighed in, acknowledging MB’s potential benefits for oxidative stress, cold prevention, and autophagy, but cautioned against the high dose Kennedy Jr. appeared to be taking. “Also that dose I don’t recommend, but he’s spearheading a movement so I get it,” Elrod said.

What is Methylene Blue?

Methylene Blue is a synthetic compound with a long history of use in medicine and industry[4]. Initially synthesized in 1876 as a textile dye, it was later discovered to have medicinal properties[4]. Today, pharmaceutical-grade MB is used to treat conditions like methemoglobinemia, where the blood is unable to effectively carry oxygen[4]. It has also found applications in treating urinary tract infections and malaria[4].

Potential Benefits of Methylene Blue

Research suggests that MB may offer a range of potential health benefits[4]:

* Cognitive Function and Memory Enhancement: MB has been shown to enhance mitochondrial function, potentially leading to improved brain function and memory[4]. It may improve brain oxygenation and circulation, supporting cognitive processes[4].
* Neuroprotective Effects: MB possesses neuroprotective properties, potentially aiding in the treatment and prevention of neurodegenerative diseases like Alzheimer’s and Parkinson’s[4][7]. Its antioxidant properties may help combat oxidative stress in neurons, a factor linked to aging and neurodegeneration[4].
* Antimicrobial Properties: MB is effective against various pathogens, including bacteria, fungi, and parasites[4].
* Antioxidant Effects: MB functions as an antioxidant, protecting cells from oxidative damage[4].
* Mood and Mental Health Support: It may have mood-stabilizing effects, potentially aiding those suffering from conditions like depression or anxiety[4].
* Energy Production and Fatigue Reduction: MB supports the production of ATP, the energy currency of cells, which can help reduce fatigue[4].
* Improving Circulation and Reducing Inflammation: MB has been found to support better circulation, help with blood flow, and reduce inflammation in various tissues[4].

Risks and Side Effects

Despite its potential benefits, Methylene Blue is not without risks[1][2].

* Serotonin Syndrome: MB carries a black box warning from the FDA due to the risk of serotonin syndrome, especially when used with serotonergic drugs like SSRIs and SNRIs[2][8]. MB inhibits monoamine oxidase A (MAO-A), potentially leading to dangerously high serotonin levels.

* Cardiovascular Reactions: High doses of MB may cause significant cardiovascular reactions[2]. Doses exceeding 2-7 mg/kg may lead to serious symptoms[2].

* G6PD Deficiency: Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid MB due to the risk of hemolytic anemia[2].

* Other Side Effects: Common side effects include nausea, vomiting, diarrhea, dizziness, headache, confusion, and blue discoloration of urine and skin[2][3]. Liver toxicity and fetal harm are also possible[3][5].

* Pro-oxidant effects: Higher doses of MB interfere with mitochondrial function and can act as a pro-oxidant, which can negate its benefits[1].

Serotonin Syndrome Risk

Methylene Blue (MB) carries a black box warning from the FDA due to its potent inhibition of monoamine oxidase A (MAO-A), an enzyme responsible for breaking down serotonin and other neurotransmitters; this inhibition can lead to dangerously elevated serotonin levels, especially when MB is used in combination with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). The resulting excessive serotonin activity can cause serotonin syndrome, a potentially life-threatening condition characterized by symptoms ranging from agitation, confusion, and rapid heart rate to muscle rigidity, hyperreflexia, seizures, and even death if untreated. Because MB prevents serotonin breakdown while SSRIs and SNRIs increase serotonin availability through reuptake inhibition, their combined use can synergistically raise serotonin to toxic levels. Additionally, MAO-A inhibition by MB can cause accumulation of tyramine, risking hypertensive crises. Therefore, co-administration of MB with other serotonergic agents is contraindicated without strict medical supervision, and patients must be closely monitored for signs of serotonin syndrome. Understanding MB’s pharmacological profile and drug interactions is critical to preventing severe adverse effects and ensuring patient safety.

G6PD Deficiency Danger

If you have a genetic disorder (G6PD deficiency), Methylene blue could kill you. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a very common genetic enzyme disorder worldwide, affecting approximately 400 million people according to multiple large-scale studies and systematic reviews. The overall global prevalence is estimated to be about 8% of the population, though this varies widely by region and population group. To get tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a healthcare provider will order a simple blood test that measures the activity level of the G6PD enzyme in your red blood cells. This test is typically performed by drawing a small sample of blood from a vein in your arm using a needle.

WARNING: One important reason for Methylene blue to be used under medical supervision is the need to screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD is an enzyme that helps protect red blood cells from oxidative stress. In individuals with G6PD deficiency, methylene blue can trigger hemolytic anemia, a condition where red blood cells break down faster than they can be replaced. This is a potentially dangerous, even fatal, reaction.

 

Methylene blue is a well-established treatment for methemoglobinemia because it helps convert methemoglobin back to normal hemoglobin, but its safe use depends critically on the presence of sufficient G6PD enzyme activity. G6PD plays a vital role in protecting red blood cells against oxidative stress by maintaining adequate levels of NADPH, which is necessary to reduce methylene blue to its active form, leukomethylene blue. In individuals with G6PD deficiency, this protective mechanism is impaired, so methylene blue cannot be effectively reduced and, paradoxically, becomes an oxidizing agent itself. This leads to increased oxidative stress, resulting in hemolytic anemia where red blood cells break down prematurely.

 

The risk of methylene blue–induced hemolysis in G6PD-deficient patients is well documented and has been reported in multiple case studies, including severe and potentially fatal reactions. For this reason, drug labels contraindicate or strongly warn against methylene blue use in known or suspected cases of G6PD deficiency. To minimize harm, it is standard medical practice to screen for G6PD deficiency prior to methylene blue administration wherever possible, especially in populations with a high prevalence of the deficiency (such as individuals from Africa, the Middle East, and parts of Asia).

Typical therapeutic doses of methylene blue for methemoglobinemia are about 1 to 2 mg/kg as a single intravenous dose, sometimes repeated if needed. Doses above 7 mg/kg can paradoxically induce methemoglobinemia by directly oxidizing hemoglobin even in people without G6PD deficiency[25][26].

In G6PD-deficient patients, even standard doses (around 1–2 mg/kg) can trigger rapid hemolysis within hours to days after administration[27][28]. Cases reported hemolysis developing within 24 to 48 hours post-treatment, sometimes requiring blood transfusions or exchange transfusions to manage severe anemia and its complications[29][30].

Checking the Evidence

While I have been clear on my concerns that the FDA might be a captured agency, I do suggest taking this warning seriously. Companies producing alternative drugs for the same indications as methylene blue (e.g., treatments for methemoglobinemia, vasoplegic syndrome, or diagnostic dyes) could have economic motives to encourage stricter warnings on MB to reduce its market share, true. MB competes with synthetic drugs and other diagnostic agents, but I don’t get the any sense so far that that behind this warning from the FDA.

There is strong and well-documented evidence that methylene blue (MB) is a potent inhibitor of monoamine oxidase A (MAO-A), which underlies its risk of causing serotonin syndrome, especially when combined with serotonergic drugs like SSRIs and SNRIs. In vitro kinetic assays have shown that MB is a tight-binding, reversible inhibitor of MAO-A with an inhibitory constant (Ki) around 27 nM, indicating very high potency at nanomolar concentrations[10]. MB binds directly to the active site of MAO-A, acting as both an oxidizing substrate and reductant, which confirms its strong interaction with the enzyme[10]. Clinical pharmacokinetic data indicate that typical intravenous doses used therapeutically (around 1 mg/kg) produce plasma concentrations sufficient to fully inhibit MAO-A in vivo, with onset of inhibition occurring within 30 minutes and lasting up to 24–48 hours after administration[9][12].

This MAO-A inhibition prevents the normal breakdown of serotonin, leading to elevated serotonin levels that can precipitate serotonin toxicity when combined with other serotonergic agents[10][12][8]. The FDA black box warning on MB reflects this risk, as multiple case reports and clinical studies have documented serotonin syndrome occurring in patients receiving MB alongside SSRIs or other serotonin reuptake inhibitors[12][15][16]. Additionally, MB inhibits MAO-B at higher concentrations but its primary clinical concern relates to MAO-A inhibition[10]. The metabolite azure B is even more potent as an MAO-A inhibitor, further contributing to this effect[11]. Overall, the biochemical, pharmacological, and clinical evidence conclusively establishes methylene blue as a potent MAO-A inhibitor responsible for increased serotonin levels and associated toxicity risks.

Dosage and Safety

Experts emphasize the importance of consulting a healthcare provider before using Methylene Blue[2][3].

“Researchers generally say that methylene blue is promising but advise against self-experimentation. We just don’t know enough about the long-term risks”[1].

The appropriate dosage varies depending on the intended use and individual factors[4]. As a supplement, a low dose of 0.5 to 4 mg may be beneficial, but higher doses carry increased risks[1].

If you weigh 180 lbs, that is 81.65 kg. If you take 10 drops of a 1% MB solution, eg. USP Gade trihydrate, that is 5 mg total, or 0.06 mg/kg.

The statement “As a supplement, a low dose of 0.5 to 4 mg may be beneficial, but higher doses carry increased risks” generally refers to a total dose in milligrams, not mg/kg. This is because typical supplement or nootropic dosing of methylene blue (MB) for general health or cognitive enhancement is often expressed as a fixed daily amount (e.g., 0.5 to 4 mg total per day), which is much lower than clinical doses used for medical conditions.

In contrast, medical dosing for conditions like methemoglobinemia or septic shock is weight-based, typically around 1 mg/kg intravenously, with some protocols allowing doses up to 5–7 mg/kg depending on severity and indication. For example, treatment doses range from 0.3 to 2 mg/kg IV, often repeated if necessary, and doses above 5 mg/kg are associated with toxicity risks.

For supplementation or off-label low-dose use, the focus is on total milligrams taken daily (e.g., 5 mg/day), which for an average adult (around 80 kg) corresponds to roughly 0.06 mg/kg, a much lower exposure than therapeutic doses.

What Doses of MB Are Considered Safe to Avoid Serotonin Syndrome?

Methylene blue (MB) is a potent reversible inhibitor of monoamine oxidase A (MAO-A) even at low doses, and this inhibition can lead to serotonin syndrome when combined with serotonergic drugs such as SSRIs and SNRIs. Evidence shows that doses less than 1 mg/kg can produce clinically significant MAO-A inhibition. Therapeutically, MB is generally considered safe at doses below 2 mg/kg, but doses above 5–7 mg/kg increase the risk of adverse effects including serotonin toxicity. Case reports and clinical studies have documented serotonin syndrome occurring at doses around 0.7–1 mg/kg in patients concurrently taking serotonergic medications. Due to this risk, the FDA advises that MB should generally not be given to patients on serotonergic drugs unless in emergency situations, where benefits may outweigh risks. In such cases, the serotonergic drug should be immediately discontinued, the lowest effective MB dose used, and the patient closely monitored for CNS toxicity for up to two weeks (or longer for fluoxetine). While doses below 0.5 mg/kg may carry lower risk, there is no universally established “safe” dose of MB to completely avoid serotonin syndrome in the presence of serotonergic drugs, so caution and medical supervision are essential.

How Long Does MB Stay In the Body?

Methylene blue (MB) is typically cleared from the body within about 24 hours after administration, with a plasma elimination half-life ranging from approximately 5 to 6.5 hours. After intravenous dosing, MB exhibits multiphasic pharmacokinetics, where the initial rapid decline in blood concentration reflects distribution into organs such as the brain, liver, and bile, followed by slower elimination. Oral bioavailability varies widely (roughly 53% to 97%), and peak plasma concentrations occur around 1 to 2 hours post-oral dose. MB is metabolized primarily to leucomethylene blue, a colorless reducing agent, which is excreted mainly via the kidneys into urine and partly in bile. About 18% to 28% of the administered dose is excreted unchanged or as metabolites in urine. The drug’s effects and presence in the body generally diminish significantly within 24 hours, although trace amounts may persist slightly longer depending on dose and individual metabolism. Overall, the combination of a 5–6.5 hour half-life and renal excretion means MB is largely cleared from the system within one day after administration.

Use Caution or Avoid MB if You Take Any of These:

Serotonergic drugs encompass a broad range of natural and artificial agents that increase serotonin levels or directly stimulate serotonin receptors. The most common class includes selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and citalopram, which block serotonin reuptake to elevate synaptic serotonin. Serotonin–norepinephrine reuptake inhibitors (SNRIs) like venlafaxine and duloxetine increase both serotonin and norepinephrine levels. Other important serotonergic drugs include serotonin receptor agonists (e.g., triptans like sumatriptan used for migraines), serotonin antagonist and reuptake inhibitors (SARIs) such as trazodone, and serotonin modulators like vortioxetine and vilazodone.

Monoamine oxidase inhibitors (MAOIs), including irreversible inhibitors like phenelzine and reversible MAO-A inhibitors such as moclobemide, prevent serotonin breakdown, significantly raising serotonin levels. Additional drugs with serotonergic properties include tricyclic antidepressants, opioids like tramadol and fentanyl, lithium, buspirone, and certain antibiotics like linezolid.

Natural substances influencing serotonin include dietary tryptophan, 5-HTP supplements, St. John’s Wort, and psychedelic compounds such as psilocybin and LSD, which act as serotonin receptor agonists.

Because these diverse agents affect serotonin through various mechanisms—reuptake inhibition, receptor stimulation, or enzyme inhibition—they can increase the risk of serotonin syndrome when combined. Understanding this wide spectrum of serotonergic drugs is crucial for safe prescribing and avoiding dangerous drug interactions.

Wait, Dietary Tryptophan? You Mean No MB with Turkey?

No, the idea that eating turkey (or other tryptophan-rich foods) combined with methylene blue (MB) poses a serotonin syndrome risk is largely a myth. While turkey and many other common foods (like chicken, cheese, milk, oats, and peanuts) contain the essential amino acid tryptophan—a precursor to serotonin—dietary tryptophan does not directly or significantly raise brain serotonin levels on its own. This is because tryptophan competes with other amino acids to cross the blood-brain barrier, and only a small fraction actually enters the brain to be converted into serotonin. Moreover, carbohydrates help facilitate tryptophan’s entry into the brain, which explains why eating a balanced meal matters more than turkey alone.

Methylene blue’s risk of serotonin syndrome arises from its potent inhibition of monoamine oxidase A (MAO-A), which blocks serotonin breakdown and can dangerously elevate serotonin levels, especially when combined with serotonergic drugs like SSRIs or SNRIs. Normal dietary intake of tryptophan from turkey or other foods is insufficient to cause serotonin toxicity by itself, even when taking MB. However, caution is warranted when MB is combined with pharmaceutical serotonergic agents, not typical dietary sources of tryptophan.

In summary, you don’t need to avoid turkey or other tryptophan-containing foods when taking methylene blue, but you must avoid combining MB with serotonergic medications to prevent serotonin syndrome. The “turkey makes you sleepy” myth is more about meal composition and digestion than tryptophan content, and dietary tryptophan alone does not pose a serotonin syndrome risk with MB.

The Bottom Line

The Methylene Blue video featuring RFK Jr. has sparked a valuable conversation about the potential benefits and risks of this compound. While research suggests promising applications, it’s crucial to approach MB with caution, consulting with a healthcare professional to determine if it’s appropriate and safe for individual use. Self-experimentation, particularly with high doses, is generally discouraged due to the potential for serious side effects. As more research emerges, a clearer understanding of MB’s role in health and wellness will hopefully develop.

DISCLAIMER: Nothing on this page is intended as medical advice. This information is presented, including links below to verify the facts, for educational purposes. Consult a qualified medical professional in an appropriate field before starting to use any drug or supplement.

Read More
^{[1] https://t-nation.com/t/possible-benefits-and-drawbacks-of-methylene-blue/289576
[2] https://www.tryeden.com/post/what-is-methylene-blue
[3] https://www.poison.org/articles/are-methylene-blue-infusions-safe-221
[4] https://www.naturemedclinic.com/methylene-blue-benefits-in-longevity-medicine/
[5] https://www.apollohospitals.com/corporate/medicines/methylene-blue/
[6] https://www.ncbi.nlm.nih.gov/books/NBK557593/
[7] https://www.news-medical.net/health/Potential-Health-Benefits-of-Methylene-Blue.aspx
[8] https://blocked.goodrx.com
[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC10774363/
[10] https://pmc.ncbi.nlm.nih.gov/articles/PMC2078225/
[11] https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.2009.06029.x
[12] https://www.apsf.org/article/methylene-blue-and-the-risk-of-serotonin-toxicity/
[13] https://www.psychotropical.com/methylene-blue-serotonin-toxicity-syndrome/
[14] https://www.sciencedirect.com/science/article/abs/pii/S0041008X11004625
[15] https://journals.lww.com/aacr/fulltext/2016/07010/patient_safety_and_methylene_blue_associated.1.aspx
[16] https://www.cureus.com/articles/340212-prevalence-of-serotonergic-drug-use-in-patients-exposed-to-perioperative-methylene-blue-a-cross-sectional-study
[17] https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/methylene-blue
[18] https://en.wikipedia.org/wiki/Methylene_blue
[19] https://pmc.ncbi.nlm.nih.gov/articles/PMC9618115/
[20] https://welltopiarx.com/unraveling-the-science-methylene-blue-metabolism-in-the-human-body/
[21] https://go.drugbank.com/drugs/DB09241
[22] https://pubmed.ncbi.nlm.nih.gov/10952480/
[23] https://asm.org/articles/2022/march/methylene-blue-the-little-known-disinfectant
[24] https://eae.edu.eu/research_article/dyedye.html
[25] https://accessmedicine.mhmedical.com/content.aspx?bookid=2284&sectionid=248385909
[26] https://accessmedicine.mhmedical.com/content.aspx?bookid=3195&sectionid=266330797
[27] https://pmc.ncbi.nlm.nih.gov/articles/PMC4091817/
[28] https://onlinelibrary.wiley.com/doi/10.1002/ajh.27324
[29] https://pmc.ncbi.nlm.nih.gov/articles/PMC5704414/
[30]  https://www.clinmedres.org/content/23/1/21.full}